According to American Society for Radiation Oncology 2010 report approximately 75% of oncology patients opt for radiation therapy. The primary aim of radiation therapy is to irradiate the tumor cells, however the normal cells being exposed to the radiation therapy get damaged. Normal tissue cells are capable of self-repair but the repetitive damage reduces the reparation properties of normal cells. Factors that increase the risk and severity of skin reactions include high daily cumulative radiation doses, the type of beam utilized for irradiation, large treatment field, treatment to areas with skin folds and whether the radiation was given with chemotherapy.
For the purpose of this study, the various products studied includes topical, dressing and oral. Topical are further classified as (antibiotics, hydrophilic creams, corticosteroids and others). Dressing are categorized as (no string barrier films, honey impregnated gauze, hydrogel and hydrocolloid dressings, silicone coated dressings and others). Market size estimates and forecast of these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.
The geographic segmentation of the global radiodermatitis market is performed for the regions North America, Europe, Asia Pacific, Latin America and Middle East and Africa markets. The regions are also further sub-segmented on the basis of major countries:
Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.
This report also includes qualitative assessment factors such as market dynamics (drivers, restraints and opportunities) to have a good understanding of the current and anticipated trends in the global radiodermatitis market. Market attractiveness assessment and competitive landscape analysis by key players are also presented in the study. Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the global radiodermatitis market. The major players in radiodermatitis market are Acelity, Alliqua Biomedical, BMG Pharma S.R.L., Convatec, Inc., Derma Sciences, Inc., Intermed Pharmaceuticals, Molnlycke Health Care AB, Smith & Nephew plc, Stratpharma AG and 3M Healthcare.
Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted
Chapter 2. Executive Summary
2.1. Global Radiodermatitis Market Portraiture
2.1.1. Global Radiodermatitis Market, by Product, 2016
2.1.2. Global Radiodermatitis Market, by Geography, 2016
Chapter 3. Global Radiodermatitis Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2016
Chapter 4. Global Radiodermatitis Market, by Product, 2015 – 2025 (US$ Mn)
4.1. Overview
4.2. Attractive Investment Proposition: Global Radiodermatitis Market, by Product
4.3. Topical
4.3.1. Antibiotics
4.3.2. Hydrophilic Creams
4.3.3. Corticosteroids
4.3.4. Others
4.4. Dressing
4.4.1. No String Barrier Films
4.4.2. Honey Impregnated Gauze
4.4.3. Hydrogel and Hydrocolloid Dressings
4.4.4. Silicone Coated Dressings
4.4.5. Others
4.5. Oral
Chapter 5. Global Radiodermatitis Market, by Geography, 2015 – 2025 (US$ Mn)
5.1. Overview
5.2. North America Radiodermatitis Market Analysis, 2015 – 2025
5.2.1. North America Radiodermatitis Market, by Product, 2015 – 2025 (US$ Mn)
5.2.2. North America Radiodermatitis Market, by Country, 2015 – 2025 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe Radiodermatitis Market Analysis, 2015 – 2025
5.3.1. Europe Radiodermatitis Market, by Product, 2015 – 2025 (US$ Mn)
5.3.2. Europe Radiodermatitis Market, by Country, 2015 – 2025 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific Radiodermatitis Market Analysis, 2015 – 2025
5.4.1. Asia Pacific Radiodermatitis Market, by Product, 2015 – 2025 (US$ Mn)
5.4.2. Asia Pacific Radiodermatitis Market, by Country, 2015 – 2025 (US$ Mn)
5.4.2.1. Japan
5.4.2.2. China
5.4.2.3. India
5.4.2.4. Rest of APAC
5.5. Latin America Radiodermatitis Market Analysis, 2015 – 2025
5.5.1. Latin America Radiodermatitis Market, by Product, 2015 – 2025 (US$ Mn)
5.5.2. Latin America Radiodermatitis Market, by Country, 2015 – 2025 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa (MEA) Radiodermatitis Market Analysis, 2015 – 2025
5.6.1. MEA Radiodermatitis Market, by Product, 2015 – 2025 (US$ Mn)
5.6.2. MEA Radiodermatitis Market, by Region, 2015 – 2025 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA
Chapter 6. Company Profiles
6.1. Acelity
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. Key Developments
6.2. Alliqua Biomedical
6.3. BMG Pharma S.R.L.
6.4. Convatec, Inc.
6.5. Derma Sciences, Inc.
6.6. Intermed Pharmaceuticals
6.7. Molnlycke Health Care AB
6.8. Smith & Nephew plc
6.9. Stratpharma AG
6.10. 3M Healthcare
6.11. Other Notable Players
List Of Table :
TABLE 1 Global Radiodermatitis Market, by Product, 2015 – 2025 (US$ Mn)
TABLE 2 Global Radiodermatitis Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 3 North America Radiodermatitis Market, by Product, 2015 – 2025 (US$ Mn)
TABLE 4 North America Radiodermatitis Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 5 Europe Radiodermatitis Market, by Product, 2015 – 2025 (US$ Mn)
TABLE 6 Europe Radiodermatitis Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 7 Asia Pacific Radiodermatitis Market, by Product, 2015 – 2025 (US$ Mn)
TABLE 8 Asia Pacific Radiodermatitis Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 9 Latin America Radiodermatitis Market, by Product, 2015 – 2025 (US$ Mn)
TABLE 10 Latin America Radiodermatitis Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 11 Middle East and Africa Radiodermatitis Market, by Product, 2015 – 2025 (US$ Mn)
TABLE 12 Middle East and Africa Radiodermatitis Market, by Region, 2015 – 2025 (US$ Mn)
TABLE 13 Acelity: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 14 Alliqua Biomedical: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 15 BMG Pharma S.R.L.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 16 Convatec, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 17 Derma Sciences, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 18 Intermed Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 19 Molnlycke Health Care AB: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 20 Smith & Nephew plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 21 Stratpharma AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 22 3M Healthcare: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
List Of Figures :
FIG. 1 Radiodermatitis: Market Segmentation
FIG. 2 Global Radiodermatitis Market Share, by Product, 2016 (Value %)
FIG. 3 Global Radiodermatitis Market Share, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition, by Geography
FIG. 5 Market Competition Landscape, by Key Players, 2016
FIG. 6 Global Topical Market, 2015 – 2025 (US$ Mn)
FIG. 7 Global Antibiotics Market, 2015 – 2025 (US$ Mn)
FIG. 8 Global Hydrophilic Creams Market, 2015 – 2025 (US$ Mn)
FIG. 9 Global Corticosteroids Market, 2015 – 2025 (US$ Mn)
FIG. 10 Global Others Topical Market, 2015 – 2025 (US$ Mn)
FIG. 11 Global Dressing Market, 2015 – 2025 (US$ Mn)
FIG. 12 Global No String Barrier Films Market, 2015 – 2025 (US$ Mn)
FIG. 13 Global Honey Impregnated Gauze Market, 2015 – 2025 (US$ Mn)
FIG. 14 Global Hydrogel and Hydrocolloid Dressings Market, 2015 – 2025 (US$ Mn)
FIG. 15 Global Silicone Coated Market, 2015 – 2025 (US$ Mn)
FIG. 16 Global Others Dressing Market, 2015 – 2025 (US$ Mn)
FIG. 17 Global Oral Market, 2015 – 2025 (US$ Mn)
FIG. 18 U.S. Radiodermatitis Market, 2015 – 2025 (US$ Mn)
FIG. 19 Canada Radiodermatitis Market, 2015 – 2025 (US$ Mn)
FIG. 20 U.K. Radiodermatitis Market, 2015 – 2025 (US$ Mn)
FIG. 21 Germany Radiodermatitis Market, 2015 – 2025 (US$ Mn)
FIG. 22 Rest of Europe Radiodermatitis Market, 2015 – 2025 (US$ Mn)
FIG. 23 Japan Radiodermatitis Market, 2015 – 2025 (US$ Mn)
FIG. 24 China Radiodermatitis Market, 2015 – 2025 (US$ Mn)
FIG. 25 India Radiodermatitis Market, 2015 – 2025 (US$ Mn)
FIG. 26 Rest of Asia Pacific Radiodermatitis Market, 2015 – 2025 (US$ Mn)
FIG. 27 Brazil Radiodermatitis Market, 2015 – 2025 (US$ Mn)
FIG. 28 Mexico Radiodermatitis Market, 2015 – 2025 (US$ Mn)
FIG. 29 Rest of Latin America Radiodermatitis Market, 2015 – 2025 (US$ Mn)
FIG. 30 GCC Radiodermatitis Market, 2015 – 2025 (US$ Mn)
FIG. 31 Rest of Middle East and Africa Radiodermatitis Market, 2015 – 2025 (US$ Mn)
Based on product types, the global radiodermatitis market is categorized into
The radiodermatitis market is driven by factors such as rising prevalence of cancer with patients opting for radiation therapy, technological advancement in the drug formulation such as hydrocolloids and hydrogels which expedites healing with minimal pain. In addition, rising physician awareness regarding disease etiology and increasing online marketing with affordable sale and purchase options will propel the market penetration of treatments. In 2016, topical segment held the largest market share chiefly due to factors such as corticosteroids are considered as the gold standard for the treatment of radiodermatitis and hydrophilic creams minimizes the patients discomfort by providing moisture to the dry desquamation skin area.
Dressings will be the fastest growing segment throughout the forecast period 2017-2025 majorly due to factors such as rising prevalence of radiodermatitis, wide range of dressings available as per the degree of skin complication due to radiation therapy. The hydrocolloid and hydrogel dressings are finding huge applications as they are used for the management of moist desquamation in order to promote a moist environment for reepithelization. The major players in radiodermatitis market are Acelity, Alliqua Biomedical, BMG Pharma S.R.L., Convatec, Inc., Derma Sciences, Inc., Intermed Pharmaceuticals, Molnlycke Health Care AB, Smith & Nephew plc., Stratpharma AG and 3M Healthcare.
For the purpose of this study, the global radiodermatitis market is categorized into the following regional and country specific markets:
North America will be the fastest growing market for radiodermatitis throughout the forecast period 2017-2025. According to the American Cancer Society, in 2017, about 1,688,780 new cancer cases were diagnosed. The dominance of North America is mainly attributed to the presence of key drivers such as rising prevalence of cancer, first treatment preference to treat cancer is given to radiation therapy, and developed research and healthcare institutions. The market growth in Europe is mainly attributed to the increasing prevalence of radiodermatitis and rising fashion trend has resulted in the demand for radiation therapy to enhance the aesthetic appeal of personal beauty and affordable reimbursement scenario.
Asia Pacific dominated the radiodermatitis market for the base year 2016 and the factors that are anticipated to propel the market growth are the increasing number of chronic health complications resulting into demand for radiation therapy, competitive market due to presence of existing major and evolving players engaged in the manufacturing and sale of radiodermatitis products in these regions, increasing disposable incomes and supportive regulatory environment for radiodermatitis products. Moreover, factors such as developing healthcare infrastructure, extensive collaborations undertaken by pharmaceutical giants to expand their product portfolio in the untapped markets of developing areas with unmet medical needs are going to fuel the rapid growth of radiodermatitis market in Latin America, and Middle East and Africa region in the near future.
